Bicalutamide 50 mg Tablets are an oral antiandrogen medicine used in the treatment of certain forms of prostate cancer. Bicalutamide belongs to a class of medicines called androgen receptor inhibitors. It works by blocking the action of androgens, including testosterone, at androgen receptors. This can help reduce androgen-driven stimulation of prostate cancer cells.
For patients, caregivers, hospitals, pharmaceutical distributors, and healthcare procurement teams searching for information about Bicalutamide 50 mg Tablets for prostate cancer, understanding the medicine's uses, mechanism, treatment role, and precautions is important.
What Is Bicalutamide 50 mg?
Bicalutamide is a nonsteroidal antiandrogen that competitively binds to androgen receptors. By preventing androgens from activating these receptors, bicalutamide can interfere with androgen-dependent prostate cancer cell activity.
The 50 mg tablet strength is an established dosage form. In the U.S. prescribing information, bicalutamide 50 mg is indicated in combination with a luteinizing hormone-releasing hormone (LHRH) analog for metastatic prostate cancer. Treatment decisions can vary according to the patient's diagnosis, disease stage, previous treatment, and local clinical guidelines.
Bicalutamide 50 mg Tablets for Prostate Cancer
Prostate cancer can be influenced by male hormones called androgens. Hormonal treatment aims either to reduce androgen levels or prevent androgens from stimulating prostate cancer cells.
Bicalutamide is an androgen receptor blocker. It prevents androgen hormones from binding to androgen receptors in target tissues. NCI explains that androgen receptor blockers are commonly used together with androgen-deprivation therapy because the combination both lowers androgen levels and blocks the action of remaining androgens.
Bicalutamide is therefore used as part of specific prostate-cancer treatment strategies rather than as a general medicine for prostate symptoms.
Uses of Bicalutamide 50 mg Tablets
The primary established use of bicalutamide 50 mg is in combination with an LHRH analog for certain patients with metastatic prostate cancer.
The exact treatment plan is determined by an oncologist or other qualified healthcare professional. Factors that may influence treatment selection include:
- Stage and spread of prostate cancer
- Previous cancer treatments
- Hormone sensitivity or resistance
- Overall medical condition
- Other medicines being taken
- Individual treatment goals
Bicalutamide should therefore be used only according to the prescribing instructions provided by a qualified healthcare professional.
How Does Bicalutamide Work?
Bicalutamide works by competitively blocking androgen receptors. Androgens can bind to these receptors and promote activity in androgen-sensitive prostate cancer cells. By blocking the receptor, bicalutamide reduces the ability of androgens to exert their effects on target tissues.
This mechanism is different from medicines that directly reduce androgen production. For this reason, bicalutamide may be combined with an LHRH agonist as part of androgen-deprivation treatment.
Bicalutamide 50 mg Dosage and Administration
The appropriate dose should always be determined by the treating physician. The U.S. prescribing information specifies one 50 mg tablet once daily when bicalutamide is used in combination with an LHRH analog for the indicated metastatic prostate-cancer setting.
Patients should not change the dose, stop treatment, or combine bicalutamide with other medicines without discussing this with their healthcare professional.
Possible Side Effects and Precautions
Like other prescription medicines, bicalutamide can cause adverse effects. Reported effects include hot flashes, nausea, breast tenderness, loss of libido, and impotence. Liver-related adverse effects have also been reported, including rare severe hepatic changes.
Patients should inform their doctor about existing liver problems and all medicines they are taking. The prescribing information also identifies important drug-interaction considerations, including interactions involving coumarin anticoagulants.
Medical supervision is important throughout treatment, particularly when symptoms or laboratory abnormalities occur.
Bicalutamide 50 mg Tablets Supply in India
For pharmaceutical distributors, hospitals, wholesalers, and institutional buyers in India, sourcing Bicalutamide 50 mg Tablets requires attention to product strength, packaging, batch details, expiry, supplier credentials, documentation, and applicable regulatory requirements.
Global Pharma Trade can support enquiries for Bicalutamide 50 mg Tablets supply in India, including discussions regarding product availability, quantities, packaging, and commercial requirements. Buyers seeking bulk pharmaceutical supply can contact the supplier with their required quantity and delivery location to request current availability and pricing.
Frequently Asked Questions
What is Bicalutamide 50 mg used for?
Bicalutamide 50 mg is an antiandrogen used in specific prostate-cancer treatment settings, including in combination with an LHRH analog for metastatic prostate cancer according to prescribing information.
Is Bicalutamide a chemotherapy medicine?
Bicalutamide is an androgen receptor blocker (antiandrogen) and is classified as hormone therapy rather than conventional cytotoxic chemotherapy.
Can Bicalutamide 50 mg be taken without a prescription?
Bicalutamide is a prescription medicine and should be used under the supervision of a qualified healthcare professional.
Where can pharmaceutical buyers source Bicalutamide 50 mg Tablets in India?
Eligible pharmaceutical and institutional buyers can contact Global Pharma Trade to enquire about Bicalutamide 50 mg Tablets availability, bulk supply, packaging, and pricing in India.
Medical disclaimer: This article is intended for general educational and pharmaceutical information. It does not replace medical advice, diagnosis, or treatment from a qualified healthcare professional. Treatment decisions should be based on the individual patient's clinical condition and the advice of their treating doctor. NCI likewise notes that its drug information is educational and not a substitute for professional medical advice.
